EN DE
Watch MustGrow Biologics Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MustGrow Biologics Corp (MGRO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of MustGrow Biologics Corp stock C$0.30, price C$0.40, that is 23.1% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials CA · ISIN CA62822A1030

MB MustGrow Biologics Corp logo Thin data Nov 10, 2026

MustGrow Biologics Corp

MGRO · V
Expensive, weak quality

Our calculation puts a fair price 23% below what the stock costs today.

Low debt
Quality 44/100
Mixed Growth (revenue 3y +985.5 %/yr in CAD)
Fair value C$0.3039 · Overvalued
Loss-making · -58.5% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 32/100
Thin data
⟳ CyclicalEstimate
Watch MustGrow Biologics Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$5.54 C$0.3050 Fair Value C$0.3039 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.3050 – C$5.54 · fair‑value band C$0.2279 – C$0.3799 · the C$0.3950 price screens above the C$0.3039 fair value. As of Nov 10, 2026.

Follow MustGrow Biologics in your weekly email

Every Wednesday you see whether MustGrow Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants.

Show moreShow less

The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage and food preservation markets.

It also offers TerraMG, a mustard-derived soil biopesticide technology. In addition, the company is developing TerraSante, an organic soil amendment and biofertility technology. Further, it sells biostimulants, micronutrients, nitrogen stabilizers, and foliars.

Additionally, the company offers biological and regenerative agriculture solutions to support sustainable farming. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018.

MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.

Stock analysis

MustGrow Biologics Corp (MGRO) currently trades at C$0.3950, while our estimate is C$0.3039, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$0.2279 (bear) to C$0.3799 (bull), the price of C$0.3950 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Basic Materials sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

MustGrow Biologics Corp reported revenue of C$8.3M in FY2025 versus C$12.9K in FY2021, a compound +403.7%/yr. Reported net income was −C$7.3M in FY2025.

Key figures

Market cap C$28.5M (≈ $20.1M) Micro · P/S ratio 2.96 · EPS (TTM) C$−0.0800 · Net margin −58.5% · Return on equity −223% · Return on assets (EBIT) −83.8% (5-year average) · Operating margin 34.7% · Revenue (TTM) C$9.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 56% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at −23%, MGRO screens richer than that median.

Fair Value

Bear C$0.2279 Fair Value C$0.3039 Bull C$0.3799
Price C$0.3950 · Downside -23.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 11
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−23,409.0% (2021) → −75.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MGRO screens overvalued: fair value 23% below the price. Compare with Nutrien Ltd →

Compare MustGrow Biologics Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 175 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −23.1% · Below median
Profitability
Net margin (12 months) −58.5% · Bottom 25%
Operating margin (12 months) 34.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 359.7% · Top 25%
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/B 32.89× · Priciest 25%
P/S (12 months) 3.00× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 17
FUTURE (revenue growth)100 · sector 14
PAST (return on equity)0 · sector 25
HEALTH (low debt)92 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Qinghai Salt Lake Industry Co 000792 ¥22.35 ¥26.81 +20% vs MGRO
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥31.99 ¥38.01 +19% vs MGRO
Nutrien Ltd NTR $72.17 $83.09 +15% vs MGRO
The Mosaic Company MOS $22.99 $25.77 +12% vs MGRO
Yara International ASA YAR kr 403.50 kr 419.83 +4% vs MGRO
ICL Group ICL $4.67 $4.84 +4% vs MGRO
CF Industries Holdings CF $122.36 $114.88 −6% vs MGRO
UPL Limited UPL ₹541.50 ₹478.29 −12% vs MGRO
Yunnan Yuntianhua Co 600096 ¥26.28 ¥17.67 −33% vs MGRO
Coromandel International Limited COROMANDEL ₹1,879 ₹1,129 −40% vs MGRO

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MustGrow Biologics Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MustGrow Biologics Corp Fair Value". https://www.fairvalue-calculator.com/stock/MGRO.V

Frequently asked questions

Is MustGrow Biologics Corp (MGRO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is C$0.3039 versus a price of C$0.3950, about 23% lower (overvalued).
What is the fair value of MGRO?
Our estimate for MustGrow Biologics Corp is C$0.3039 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$0.3950.
What is the quality score of MGRO?
MustGrow Biologics Corp has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MustGrow Biologics Corp (MGRO)?
Our calculated price target is the estimate of C$0.3039 (as of Nov 10, 2026). Cautious scenario C$0.2279, optimistic scenario C$0.3799. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the MustGrow Biologics Corp stock forecast for 2026?
Our estimate puts fair value at C$0.3039, about 23% lower versus a price of C$0.3950 (overvalued). Cautious scenario C$0.2279, optimistic scenario C$0.3799. The calculation is refreshed regularly with new filings.
What is the revenue of MustGrow Biologics Corp (MGRO)?
MustGrow Biologics Corp reported trailing-twelve-month revenue of about C$9.5M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of MustGrow Biologics Corp (MGRO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MustGrow Biologics Corp it is C$0.3039 per share (as of Nov 10, 2026), against a price of C$0.3950.
Is MustGrow Biologics Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MGRO trades above its calculated fair value: price C$0.3950, fair value C$0.3039, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MGRO?
No. The price is what the market pays today (C$0.3950); the fair value is what the company's own numbers justify (C$0.3039). For MustGrow Biologics Corp the two are C$0.0911 per share apart. That gap is exactly why we show both numbers side by side.
How much is MustGrow Biologics Corp worth?
The market values MustGrow Biologics Corp at about C$28.5M (market capitalisation, as of Nov 10, 2026). Per share that is C$0.3950; our models calculate a fair value of C$0.3039 per share.
What do the bullish and bearish scenarios say about MGRO?
Our models span a range for MustGrow Biologics Corp: cautious scenario C$0.2279, base C$0.3039, optimistic C$0.3799 per share (as of Nov 10, 2026, price C$0.3950). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MustGrow Biologics Corp (MGRO)?
Balance-sheet figures for MustGrow Biologics Corp (as of Nov 10, 2026): return on equity −222.5%, debt of 0.15 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is MGRO from its 52-week high?
MustGrow Biologics Corp trades at C$0.3950, about 56% below its 52-week high of C$0.9000 and 30% above the low of C$0.3050 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.3039 is for.
Which stocks are comparable to MustGrow Biologics Corp?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MustGrow Biologics Corp stock attractive at the current price?
The data as of Nov 10, 2026: price C$0.3950, calculated fair value C$0.3039 (−23%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. MustGrow Biologics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MustGrow Biologics Corp (MGRO)?
The closing price on Nov 10, 2026 was C$0.3950. Our estimate is C$0.3039, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MustGrow Biologics Corp right now?
The price sits above even our optimistic bull case (C$0.3799). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of MustGrow Biologics Corp

How large is the market capitalisation of MustGrow Biologics Corp (MGRO)?
The market capitalisation of MustGrow Biologics Corp is C$28.5M (≈ $20.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MustGrow Biologics Corp (MGRO)?
The price-to-sales ratio of MustGrow Biologics Corp is 2.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MustGrow Biologics Corp (MGRO)?
Earnings per share at MustGrow Biologics Corp are C$−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MustGrow Biologics Corp (MGRO)?
The net margin of MustGrow Biologics Corp is −58.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MustGrow Biologics Corp (MGRO)?
The return on equity (ROE) of MustGrow Biologics Corp is −223% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MustGrow Biologics Corp (MGRO)?
On an EBIT basis the return on assets of MustGrow Biologics Corp is −83.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MustGrow Biologics Corp (MGRO)?
The operating margin of MustGrow Biologics Corp is 34.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MustGrow Biologics Corp (MGRO)?
Revenue at MustGrow Biologics Corp is growing +360% versus a year earlier (3y avg +985%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MustGrow Biologics Corp (MGRO) generate?
The free cash flow of MustGrow Biologics Corp is −C$5.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch MustGrow Biologics Corp in the live analysis

One click puts MustGrow Biologics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.